Patents by Inventor Matthew J. Bernett

Matthew J. Bernett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
    Publication number: 20170335013
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Application
    Filed: March 16, 2017
    Publication date: November 23, 2017
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Optimized antibodies that target CD19
    Patent number: 9803020
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: October 31, 2017
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Heterodimeric proteins
    Patent number: 9701759
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: July 11, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS
    Publication number: 20170174757
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 22, 2017
    Inventors: Gregory Lazar, Bassil I. Dahiyat, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9617348
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: April 11, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Antibodies with modified isoelectric points
    Patent number: 9605061
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 28, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Matthew J. Bernett
  • HETERODIMERIC ANTIBODIES TO CD3 X CD123
    Publication number: 20170081424
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: June 17, 2016
    Publication date: March 23, 2017
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • HETERODIMERIC ANTIBODIES TO CD3 X CD123
    Publication number: 20170081420
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: June 17, 2016
    Publication date: March 23, 2017
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9540451
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: January 10, 2017
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20160355608
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: April 28, 2016
    Publication date: December 8, 2016
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20160264643
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: May 19, 2016
    Publication date: September 15, 2016
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20160229924
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: November 25, 2015
    Publication date: August 11, 2016
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
    Publication number: 20160215063
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Application
    Filed: November 25, 2015
    Publication date: July 28, 2016
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • HETERODIMERIC ANTIBODIES INCLUDING BINDING TO CD8
    Publication number: 20160176969
    Abstract: The invention provides bispecific antibodies that co-engage CD8 (preferably bivalently) and a target tumor antigen.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 23, 2016
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee
  • CTLA4-Ig immunoadhesins
    Patent number: 9371397
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: June 21, 2016
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS AND IMMUNOFILTERING
    Publication number: 20160068588
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: September 14, 2015
    Publication date: March 10, 2016
    Inventors: Matthew J. Bernett, Bassil Dahiyat, John Desjarlais, Gregory A. Lazar, Gregory L. Moore
  • RAPID CLEARANCE OF ANTIGEN COMPLEXES USING NOVEL ANTIBODIES
    Publication number: 20160060360
    Abstract: The present invention relates to rapid clearance molecules that bind target antigens and Fc?RIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions.
    Type: Application
    Filed: July 24, 2015
    Publication date: March 3, 2016
    Inventors: Gregory L. Moore, John Desjarlais, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9266966
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 23, 2016
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9221916
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: December 29, 2015
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Compositions and methods for treating IgE-mediated disorders
    Patent number: 9062117
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: June 23, 2015
    Assignee: Xencor, Inc.
    Inventors: John Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett